Activated thrombin activatable fibrinolysis inhibitor (TAFIa) is associated with inflammatory markers in inflammatory bowel diseases Danuta Owczarek, Anetta Undas, Jonathan H. Foley, Michael E. Nesheim, Konrad Jabłonski, Tomasz Mach Journal of Crohn's and Colitis Volume 6, Issue 1, Pages 13-20 (February 2012) DOI: 10.1016/j.crohns.2011.06.005 Copyright © 2011 European Crohn's and Colitis Organisation Terms and Conditions
Figure 1 Correlations between TAFIa and a) white blood cells, b) CRP, c) fibrinogen, d) albumin, and e) activity in patients with ulcerative colitis. Journal of Crohn's and Colitis 2012 6, 13-20DOI: (10.1016/j.crohns.2011.06.005) Copyright © 2011 European Crohn's and Colitis Organisation Terms and Conditions
Figure 2 Correlations between TAFIa and a) platelets, b) CRP, c) fibrinogen, and d) albumin in patients with Crohn's disease. Journal of Crohn's and Colitis 2012 6, 13-20DOI: (10.1016/j.crohns.2011.06.005) Copyright © 2011 European Crohn's and Colitis Organisation Terms and Conditions
Figure 3 Dispersion graphs of the TAFIa for: active Crohn's disesase (CDactive), nonactive Crohn's disease (CDnactiv), active ulcerative colitis (UCactiv) and nonactive ulcerative colitis (UCnactiv). Journal of Crohn's and Colitis 2012 6, 13-20DOI: (10.1016/j.crohns.2011.06.005) Copyright © 2011 European Crohn's and Colitis Organisation Terms and Conditions